nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00718	0.0964	CbGpPWpGaD
Epoprostenol—PTGIS—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00582	0.0782	CbGpPWpGaD
Epoprostenol—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00451	0.0605	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—CYP2S1—psoriasis	0.00309	0.0415	CbGpPWpGaD
Epoprostenol—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.0028	0.0375	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—HCAR2—psoriasis	0.00212	0.0284	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SERPINB8—psoriasis	0.00189	0.0254	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SERPINB8—psoriasis	0.00174	0.0234	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00169	0.0226	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00155	0.0208	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00155	0.0208	CbGpPWpGaD
Epoprostenol—PTGIS—endothelium—psoriasis	0.00147	0.527	CbGeAlD
Epoprostenol—P2RY12—GPCR ligand binding—HCAR2—psoriasis	0.00128	0.0172	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—SOCS1—psoriasis	0.00122	0.0164	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—ICAM1—psoriasis	0.00122	0.0163	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—HCAR2—psoriasis	0.00118	0.0159	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HCAR2—psoriasis	0.00118	0.0159	CbGpPWpGaD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00116	0.0156	CbGpPWpGaD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00115	0.0154	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CCL20—psoriasis	0.0011	0.0148	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000941	0.0126	CbGpPWpGaD
Epoprostenol—PTGIR—Platelet homeostasis—NOS2—psoriasis	0.000927	0.0124	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—LEP—psoriasis	0.000903	0.0121	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000875	0.0117	CbGpPWpGaD
Epoprostenol—PTGIR—endothelium—psoriasis	0.000844	0.302	CbGeAlD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000806	0.0108	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000806	0.0108	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—PPARG—psoriasis	0.000787	0.0106	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HCAR2—psoriasis	0.000725	0.00973	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HCAR2—psoriasis	0.000667	0.00896	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HCAR2—psoriasis	0.000667	0.00896	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCL20—psoriasis	0.000667	0.00895	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HCAR2—psoriasis	0.000659	0.00884	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NDUFA5—psoriasis	0.000622	0.00835	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL20—psoriasis	0.000613	0.00823	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL20—psoriasis	0.000613	0.00823	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HCAR2—psoriasis	0.000606	0.00813	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HCAR2—psoriasis	0.000606	0.00813	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.00058	0.00779	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ITGAL—psoriasis	0.00055	0.00738	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000533	0.00716	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP2S1—psoriasis	0.000529	0.0071	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—ITGAL—psoriasis	0.000506	0.00679	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.0005	0.00671	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000493	0.00662	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—STAT3—psoriasis	0.000483	0.00648	CbGpPWpGaD
Epoprostenol—PTGIS—tendon—psoriasis	0.000477	0.171	CbGeAlD
Epoprostenol—Syncope—Betamethasone—psoriasis	0.000436	0.000472	CcSEcCtD
Epoprostenol—Pain—Mycophenolate mofetil—psoriasis	0.000436	0.000472	CcSEcCtD
Epoprostenol—Constipation—Mycophenolate mofetil—psoriasis	0.000436	0.000472	CcSEcCtD
Epoprostenol—Infection—Triamcinolone—psoriasis	0.000434	0.000471	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—psoriasis	0.000434	0.00047	CcSEcCtD
Epoprostenol—Hypotension—Hydrocortisone—psoriasis	0.000434	0.00047	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—psoriasis	0.000432	0.000468	CcSEcCtD
Epoprostenol—Shock—Triamcinolone—psoriasis	0.00043	0.000466	CcSEcCtD
Epoprostenol—Insomnia—Prednisolone—psoriasis	0.00043	0.000466	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Cyclosporine—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Loss of consciousness—Dexamethasone—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Loss of consciousness—Betamethasone—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Dizziness—Mycophenolic acid—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisolone—psoriasis	0.000427	0.000463	CcSEcCtD
Epoprostenol—Tachycardia—Triamcinolone—psoriasis	0.000427	0.000462	CcSEcCtD
Epoprostenol—Mental disorder—Prednisone—psoriasis	0.000426	0.000462	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000423	0.000458	CcSEcCtD
Epoprostenol—Hyperhidrosis—Triamcinolone—psoriasis	0.000423	0.000458	CcSEcCtD
Epoprostenol—Insomnia—Hydrocortisone—psoriasis	0.00042	0.000455	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—TNF—psoriasis	0.000418	0.00561	CbGpPWpGaD
Epoprostenol—Paraesthesia—Hydrocortisone—psoriasis	0.000417	0.000452	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000417	0.000452	CcSEcCtD
Epoprostenol—Urticaria—Cyclosporine—psoriasis	0.000415	0.00045	CcSEcCtD
Epoprostenol—Myalgia—Dexamethasone—psoriasis	0.000414	0.000448	CcSEcCtD
Epoprostenol—Myalgia—Betamethasone—psoriasis	0.000414	0.000448	CcSEcCtD
Epoprostenol—Body temperature increased—Cyclosporine—psoriasis	0.000413	0.000448	CcSEcCtD
Epoprostenol—Abdominal pain—Cyclosporine—psoriasis	0.000413	0.000448	CcSEcCtD
Epoprostenol—Anxiety—Dexamethasone—psoriasis	0.000412	0.000447	CcSEcCtD
Epoprostenol—Anxiety—Betamethasone—psoriasis	0.000412	0.000447	CcSEcCtD
Epoprostenol—Vomiting—Mycophenolic acid—psoriasis	0.000411	0.000445	CcSEcCtD
Epoprostenol—Dyspepsia—Hydrocortisone—psoriasis	0.000409	0.000443	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—psoriasis	0.000408	0.000443	CcSEcCtD
Epoprostenol—Rash—Mycophenolic acid—psoriasis	0.000407	0.000441	CcSEcCtD
Epoprostenol—Dermatitis—Mycophenolic acid—psoriasis	0.000407	0.000441	CcSEcCtD
Epoprostenol—Pain—Prednisolone—psoriasis	0.000406	0.000441	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—psoriasis	0.000406	0.00044	CcSEcCtD
Epoprostenol—Urticaria—Mycophenolate mofetil—psoriasis	0.000405	0.000439	CcSEcCtD
Epoprostenol—Headache—Mycophenolic acid—psoriasis	0.000404	0.000438	CcSEcCtD
Epoprostenol—Decreased appetite—Hydrocortisone—psoriasis	0.000404	0.000437	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—psoriasis	0.000403	0.000437	CcSEcCtD
Epoprostenol—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000403	0.000437	CcSEcCtD
Epoprostenol—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000403	0.000437	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000401	0.000434	CcSEcCtD
Epoprostenol—Fatigue—Hydrocortisone—psoriasis	0.0004	0.000434	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000398	0.000432	CcSEcCtD
Epoprostenol—Pain—Hydrocortisone—psoriasis	0.000397	0.00043	CcSEcCtD
Epoprostenol—Anaphylactic shock—Dexamethasone—psoriasis	0.000397	0.00043	CcSEcCtD
Epoprostenol—Oedema—Dexamethasone—psoriasis	0.000397	0.00043	CcSEcCtD
Epoprostenol—Anaphylactic shock—Betamethasone—psoriasis	0.000397	0.00043	CcSEcCtD
Epoprostenol—Oedema—Betamethasone—psoriasis	0.000397	0.00043	CcSEcCtD
Epoprostenol—Insomnia—Triamcinolone—psoriasis	0.000395	0.000428	CcSEcCtD
Epoprostenol—Infection—Betamethasone—psoriasis	0.000394	0.000427	CcSEcCtD
Epoprostenol—Infection—Dexamethasone—psoriasis	0.000394	0.000427	CcSEcCtD
Epoprostenol—Paraesthesia—Triamcinolone—psoriasis	0.000392	0.000425	CcSEcCtD
Epoprostenol—Anaemia—Prednisone—psoriasis	0.000391	0.000424	CcSEcCtD
Epoprostenol—Shock—Betamethasone—psoriasis	0.00039	0.000423	CcSEcCtD
Epoprostenol—Shock—Dexamethasone—psoriasis	0.00039	0.000423	CcSEcCtD
Epoprostenol—Dyspnoea—Triamcinolone—psoriasis	0.00039	0.000422	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—HCAR2—psoriasis	0.000389	0.00522	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Dexamethasone—psoriasis	0.000389	0.000422	CcSEcCtD
Epoprostenol—Nervous system disorder—Betamethasone—psoriasis	0.000389	0.000422	CcSEcCtD
Epoprostenol—Agitation—Prednisone—psoriasis	0.000389	0.000421	CcSEcCtD
Epoprostenol—Thrombocytopenia—Dexamethasone—psoriasis	0.000388	0.000421	CcSEcCtD
Epoprostenol—Thrombocytopenia—Betamethasone—psoriasis	0.000388	0.000421	CcSEcCtD
Epoprostenol—Tachycardia—Dexamethasone—psoriasis	0.000387	0.00042	CcSEcCtD
Epoprostenol—Tachycardia—Betamethasone—psoriasis	0.000387	0.00042	CcSEcCtD
Epoprostenol—Hypersensitivity—Cyclosporine—psoriasis	0.000385	0.000417	CcSEcCtD
Epoprostenol—Dyspepsia—Triamcinolone—psoriasis	0.000385	0.000417	CcSEcCtD
Epoprostenol—Nausea—Mycophenolic acid—psoriasis	0.000384	0.000416	CcSEcCtD
Epoprostenol—Hyperhidrosis—Betamethasone—psoriasis	0.000383	0.000416	CcSEcCtD
Epoprostenol—Hyperhidrosis—Dexamethasone—psoriasis	0.000383	0.000416	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00038	0.000411	CcSEcCtD
Epoprostenol—Syncope—Prednisone—psoriasis	0.00038	0.000411	CcSEcCtD
Epoprostenol—Anorexia—Dexamethasone—psoriasis	0.000378	0.00041	CcSEcCtD
Epoprostenol—Anorexia—Betamethasone—psoriasis	0.000378	0.00041	CcSEcCtD
Epoprostenol—Urticaria—Prednisolone—psoriasis	0.000378	0.000409	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—psoriasis	0.000377	0.000409	CcSEcCtD
Epoprostenol—Fatigue—Triamcinolone—psoriasis	0.000377	0.000408	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CCL20—psoriasis	0.000377	0.00506	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000375	0.000407	CcSEcCtD
Epoprostenol—Asthenia—Cyclosporine—psoriasis	0.000375	0.000406	CcSEcCtD
Epoprostenol—Pain—Triamcinolone—psoriasis	0.000374	0.000405	CcSEcCtD
Epoprostenol—Loss of consciousness—Prednisone—psoriasis	0.000372	0.000403	CcSEcCtD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000372	0.00499	CbGpPWpGaD
Epoprostenol—Hypotension—Dexamethasone—psoriasis	0.000371	0.000402	CcSEcCtD
Epoprostenol—Hypotension—Betamethasone—psoriasis	0.000371	0.000402	CcSEcCtD
Epoprostenol—Pruritus—Cyclosporine—psoriasis	0.00037	0.000401	CcSEcCtD
Epoprostenol—Urticaria—Hydrocortisone—psoriasis	0.000369	0.0004	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—psoriasis	0.000369	0.0004	CcSEcCtD
Epoprostenol—Abdominal pain—Hydrocortisone—psoriasis	0.000367	0.000398	CcSEcCtD
Epoprostenol—Body temperature increased—Hydrocortisone—psoriasis	0.000367	0.000398	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—psoriasis	0.000366	0.000397	CcSEcCtD
Epoprostenol—Asthenia—Mycophenolate mofetil—psoriasis	0.000366	0.000396	CcSEcCtD
Epoprostenol—Chills—Methotrexate—psoriasis	0.000365	0.000395	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000361	0.000392	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000361	0.000392	CcSEcCtD
Epoprostenol—Pruritus—Mycophenolate mofetil—psoriasis	0.000361	0.000391	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—psoriasis	0.00036	0.00039	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—psoriasis	0.00036	0.00039	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—psoriasis	0.000359	0.000389	CcSEcCtD
Epoprostenol—Insomnia—Betamethasone—psoriasis	0.000359	0.000389	CcSEcCtD
Epoprostenol—Insomnia—Dexamethasone—psoriasis	0.000359	0.000389	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—HCAR2—psoriasis	0.000358	0.00481	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HCAR2—psoriasis	0.000358	0.00481	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000358	0.000388	CcSEcCtD
Epoprostenol—Diarrhoea—Cyclosporine—psoriasis	0.000357	0.000387	CcSEcCtD
Epoprostenol—Paraesthesia—Dexamethasone—psoriasis	0.000356	0.000386	CcSEcCtD
Epoprostenol—Paraesthesia—Betamethasone—psoriasis	0.000356	0.000386	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—psoriasis	0.000356	0.000386	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisolone—psoriasis	0.00035	0.00038	CcSEcCtD
Epoprostenol—Dyspepsia—Betamethasone—psoriasis	0.000349	0.000378	CcSEcCtD
Epoprostenol—Dyspepsia—Dexamethasone—psoriasis	0.000349	0.000378	CcSEcCtD
Epoprostenol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000349	0.000378	CcSEcCtD
Epoprostenol—Urticaria—Triamcinolone—psoriasis	0.000347	0.000376	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—CCL20—psoriasis	0.000347	0.00465	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CCL20—psoriasis	0.000347	0.00465	CbGpPWpGaD
Epoprostenol—Body temperature increased—Triamcinolone—psoriasis	0.000346	0.000374	CcSEcCtD
Epoprostenol—Dizziness—Cyclosporine—psoriasis	0.000345	0.000374	CcSEcCtD
Epoprostenol—Oedema—Prednisone—psoriasis	0.000345	0.000374	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—psoriasis	0.000345	0.000374	CcSEcCtD
Epoprostenol—Decreased appetite—Betamethasone—psoriasis	0.000345	0.000374	CcSEcCtD
Epoprostenol—Decreased appetite—Dexamethasone—psoriasis	0.000345	0.000374	CcSEcCtD
Epoprostenol—Infection—Prednisone—psoriasis	0.000343	0.000372	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Betamethasone—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCL20—psoriasis	0.000342	0.00459	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Hydrocortisone—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—Fatigue—Betamethasone—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—Fatigue—Dexamethasone—psoriasis	0.000342	0.000371	CcSEcCtD
Epoprostenol—Shock—Prednisone—psoriasis	0.00034	0.000368	CcSEcCtD
Epoprostenol—Pain—Dexamethasone—psoriasis	0.000339	0.000368	CcSEcCtD
Epoprostenol—Pain—Betamethasone—psoriasis	0.000339	0.000368	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—psoriasis	0.000339	0.000367	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000337	0.00453	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TAGAP—psoriasis	0.000337	0.00453	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—IL6—psoriasis	0.000337	0.00453	CbGpPWpGaD
Epoprostenol—Tachycardia—Prednisone—psoriasis	0.000337	0.000365	CcSEcCtD
Epoprostenol—Dizziness—Mycophenolate mofetil—psoriasis	0.000337	0.000365	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—psoriasis	0.000335	0.000364	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—psoriasis	0.000334	0.000362	CcSEcCtD
Epoprostenol—Asthenia—Hydrocortisone—psoriasis	0.000333	0.000361	CcSEcCtD
Epoprostenol—Vomiting—Cyclosporine—psoriasis	0.000332	0.00036	CcSEcCtD
Epoprostenol—Rash—Cyclosporine—psoriasis	0.000329	0.000357	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—psoriasis	0.000329	0.000357	CcSEcCtD
Epoprostenol—Dermatitis—Cyclosporine—psoriasis	0.000329	0.000357	CcSEcCtD
Epoprostenol—Pruritus—Hydrocortisone—psoriasis	0.000328	0.000356	CcSEcCtD
Epoprostenol—Headache—Cyclosporine—psoriasis	0.000327	0.000355	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—psoriasis	0.000327	0.000354	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Dexamethasone—psoriasis	0.000324	0.000351	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Betamethasone—psoriasis	0.000324	0.000351	CcSEcCtD
Epoprostenol—Vomiting—Mycophenolate mofetil—psoriasis	0.000324	0.000351	CcSEcCtD
Epoprostenol—Hypersensitivity—Triamcinolone—psoriasis	0.000322	0.000349	CcSEcCtD
Epoprostenol—Rash—Mycophenolate mofetil—psoriasis	0.000321	0.000348	CcSEcCtD
Epoprostenol—Dermatitis—Mycophenolate mofetil—psoriasis	0.000321	0.000348	CcSEcCtD
Epoprostenol—Headache—Mycophenolate mofetil—psoriasis	0.000319	0.000346	CcSEcCtD
Epoprostenol—Diarrhoea—Hydrocortisone—psoriasis	0.000318	0.000344	CcSEcCtD
Epoprostenol—Urticaria—Dexamethasone—psoriasis	0.000315	0.000341	CcSEcCtD
Epoprostenol—Urticaria—Betamethasone—psoriasis	0.000315	0.000341	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CCL20—psoriasis	0.000315	0.00423	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL20—psoriasis	0.000315	0.00423	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Prednisone—psoriasis	0.000315	0.000341	CcSEcCtD
Epoprostenol—Dizziness—Prednisolone—psoriasis	0.000314	0.000341	CcSEcCtD
Epoprostenol—Asthenia—Triamcinolone—psoriasis	0.000314	0.00034	CcSEcCtD
Epoprostenol—Abdominal pain—Dexamethasone—psoriasis	0.000314	0.00034	CcSEcCtD
Epoprostenol—Body temperature increased—Betamethasone—psoriasis	0.000314	0.00034	CcSEcCtD
Epoprostenol—Body temperature increased—Dexamethasone—psoriasis	0.000314	0.00034	CcSEcCtD
Epoprostenol—Abdominal pain—Betamethasone—psoriasis	0.000314	0.00034	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—psoriasis	0.000312	0.000339	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—TAGAP—psoriasis	0.00031	0.00417	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TAGAP—psoriasis	0.00031	0.00417	CbGpPWpGaD
Epoprostenol—Nausea—Cyclosporine—psoriasis	0.00031	0.000336	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisone—psoriasis	0.00031	0.000336	CcSEcCtD
Epoprostenol—Pruritus—Triamcinolone—psoriasis	0.000309	0.000335	CcSEcCtD
Epoprostenol—Cough—Methotrexate—psoriasis	0.000309	0.000334	CcSEcCtD
Epoprostenol—Dizziness—Hydrocortisone—psoriasis	0.000307	0.000333	CcSEcCtD
Epoprostenol—Dyspepsia—Prednisone—psoriasis	0.000304	0.00033	CcSEcCtD
Epoprostenol—Nausea—Mycophenolate mofetil—psoriasis	0.000303	0.000328	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—psoriasis	0.000301	0.000326	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—psoriasis	0.000301	0.000326	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—psoriasis	0.000301	0.000326	CcSEcCtD
Epoprostenol—Decreased appetite—Prednisone—psoriasis	0.0003	0.000325	CcSEcCtD
Epoprostenol—Rash—Prednisolone—psoriasis	0.0003	0.000325	CcSEcCtD
Epoprostenol—Dermatitis—Prednisolone—psoriasis	0.000299	0.000324	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000299	0.000324	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—psoriasis	0.000298	0.000323	CcSEcCtD
Epoprostenol—Headache—Prednisolone—psoriasis	0.000298	0.000323	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL8—psoriasis	0.000297	0.00399	CbGpPWpGaD
Epoprostenol—Constipation—Prednisone—psoriasis	0.000295	0.00032	CcSEcCtD
Epoprostenol—Vomiting—Hydrocortisone—psoriasis	0.000295	0.00032	CcSEcCtD
Epoprostenol—Rash—Hydrocortisone—psoriasis	0.000293	0.000317	CcSEcCtD
Epoprostenol—Dermatitis—Hydrocortisone—psoriasis	0.000292	0.000317	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—psoriasis	0.000291	0.000315	CcSEcCtD
Epoprostenol—Headache—Hydrocortisone—psoriasis	0.000291	0.000315	CcSEcCtD
Epoprostenol—Dizziness—Triamcinolone—psoriasis	0.000289	0.000313	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—psoriasis	0.000289	0.000313	CcSEcCtD
Epoprostenol—Infection—Methotrexate—psoriasis	0.000287	0.000311	CcSEcCtD
Epoprostenol—Asthenia—Dexamethasone—psoriasis	0.000285	0.000308	CcSEcCtD
Epoprostenol—Asthenia—Betamethasone—psoriasis	0.000285	0.000308	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—psoriasis	0.000283	0.000307	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—psoriasis	0.000283	0.000306	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Prednisone—psoriasis	0.000282	0.000306	CcSEcCtD
Epoprostenol—Nausea—Prednisolone—psoriasis	0.000282	0.000306	CcSEcCtD
Epoprostenol—Pruritus—Betamethasone—psoriasis	0.000281	0.000304	CcSEcCtD
Epoprostenol—Pruritus—Dexamethasone—psoriasis	0.000281	0.000304	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—psoriasis	0.00028	0.000304	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—psoriasis	0.000279	0.000302	CcSEcCtD
Epoprostenol—Vomiting—Triamcinolone—psoriasis	0.000278	0.000301	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000277	0.00372	CbGpPWpGaD
Epoprostenol—Nausea—Hydrocortisone—psoriasis	0.000276	0.000299	CcSEcCtD
Epoprostenol—Rash—Triamcinolone—psoriasis	0.000276	0.000299	CcSEcCtD
Epoprostenol—Dermatitis—Triamcinolone—psoriasis	0.000275	0.000298	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—psoriasis	0.000275	0.000298	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—psoriasis	0.000274	0.000297	CcSEcCtD
Epoprostenol—Headache—Triamcinolone—psoriasis	0.000274	0.000297	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—psoriasis	0.000273	0.000296	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—psoriasis	0.000273	0.000296	CcSEcCtD
Epoprostenol—Diarrhoea—Betamethasone—psoriasis	0.000271	0.000294	CcSEcCtD
Epoprostenol—Diarrhoea—Dexamethasone—psoriasis	0.000271	0.000294	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—psoriasis	0.00027	0.000292	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000263	0.000285	CcSEcCtD
Epoprostenol—Dizziness—Betamethasone—psoriasis	0.000262	0.000284	CcSEcCtD
Epoprostenol—Dizziness—Dexamethasone—psoriasis	0.000262	0.000284	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—psoriasis	0.000261	0.000283	CcSEcCtD
Epoprostenol—Nausea—Triamcinolone—psoriasis	0.00026	0.000281	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—psoriasis	0.000259	0.000281	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CARM1—psoriasis	0.000258	0.00347	CbGpPWpGaD
Epoprostenol—Dyspnoea—Methotrexate—psoriasis	0.000257	0.000279	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—psoriasis	0.000257	0.000278	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisone—psoriasis	0.000254	0.000276	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—psoriasis	0.000254	0.000275	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000254	0.0034	CbGpPWpGaD
Epoprostenol—Vomiting—Dexamethasone—psoriasis	0.000252	0.000273	CcSEcCtD
Epoprostenol—Vomiting—Betamethasone—psoriasis	0.000252	0.000273	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—psoriasis	0.000251	0.000272	CcSEcCtD
Epoprostenol—Rash—Betamethasone—psoriasis	0.00025	0.000271	CcSEcCtD
Epoprostenol—Rash—Dexamethasone—psoriasis	0.00025	0.000271	CcSEcCtD
Epoprostenol—Dermatitis—Dexamethasone—psoriasis	0.00025	0.000271	CcSEcCtD
Epoprostenol—Dermatitis—Betamethasone—psoriasis	0.00025	0.000271	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—psoriasis	0.000249	0.00027	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—psoriasis	0.000249	0.00027	CcSEcCtD
Epoprostenol—Headache—Dexamethasone—psoriasis	0.000248	0.000269	CcSEcCtD
Epoprostenol—Headache—Betamethasone—psoriasis	0.000248	0.000269	CcSEcCtD
Epoprostenol—Asthenia—Prednisone—psoriasis	0.000248	0.000269	CcSEcCtD
Epoprostenol—Pain—Methotrexate—psoriasis	0.000247	0.000268	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—psoriasis	0.000244	0.000265	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000242	0.00324	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000236	0.00317	CbGpPWpGaD
Epoprostenol—Diarrhoea—Prednisone—psoriasis	0.000236	0.000256	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—psoriasis	0.000236	0.000256	CcSEcCtD
Epoprostenol—Nausea—Betamethasone—psoriasis	0.000236	0.000255	CcSEcCtD
Epoprostenol—Nausea—Dexamethasone—psoriasis	0.000236	0.000255	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—psoriasis	0.000229	0.000249	CcSEcCtD
Epoprostenol—Dizziness—Prednisone—psoriasis	0.000228	0.000248	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—psoriasis	0.000228	0.000247	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—psoriasis	0.000228	0.000247	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—NOS2—psoriasis	0.000226	0.00303	CbGpPWpGaD
Epoprostenol—Vomiting—Prednisone—psoriasis	0.00022	0.000238	CcSEcCtD
Epoprostenol—Rash—Prednisone—psoriasis	0.000218	0.000236	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—psoriasis	0.000218	0.000236	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000218	0.00292	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000218	0.00292	CbGpPWpGaD
Epoprostenol—Headache—Prednisone—psoriasis	0.000216	0.000235	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—psoriasis	0.000213	0.00023	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—NOS2—psoriasis	0.000208	0.00279	CbGpPWpGaD
Epoprostenol—Asthenia—Methotrexate—psoriasis	0.000207	0.000224	CcSEcCtD
Epoprostenol—Nausea—Prednisone—psoriasis	0.000205	0.000222	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—psoriasis	0.000204	0.000221	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CCL20—psoriasis	0.000202	0.00271	CbGpPWpGaD
Epoprostenol—Diarrhoea—Methotrexate—psoriasis	0.000198	0.000214	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—psoriasis	0.000191	0.000207	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—CCL20—psoriasis	0.000186	0.0025	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL20—psoriasis	0.000186	0.0025	CbGpPWpGaD
Epoprostenol—Vomiting—Methotrexate—psoriasis	0.000184	0.000199	CcSEcCtD
Epoprostenol—Rash—Methotrexate—psoriasis	0.000182	0.000197	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—psoriasis	0.000182	0.000197	CcSEcCtD
Epoprostenol—Headache—Methotrexate—psoriasis	0.000181	0.000196	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL8—psoriasis	0.00018	0.00242	CbGpPWpGaD
Epoprostenol—Nausea—Methotrexate—psoriasis	0.000171	0.000186	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL8—psoriasis	0.000166	0.00222	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL8—psoriasis	0.000166	0.00222	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000165	0.00221	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CAT—psoriasis	0.000159	0.00213	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HLA-A—psoriasis	0.000158	0.00212	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOE—psoriasis	0.000147	0.00198	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS2—psoriasis	0.000137	0.00184	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—psoriasis	0.000131	0.00175	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—psoriasis	0.000123	0.00166	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—psoriasis	0.00012	0.00161	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TYK2—psoriasis	0.000113	0.00151	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SOCS1—psoriasis	0.000111	0.00149	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—psoriasis	0.000108	0.00144	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—TYK2—psoriasis	0.000106	0.00142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SOCS1—psoriasis	0.000102	0.00137	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SOCS1—psoriasis	0.000102	0.00137	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—psoriasis	0.000102	0.00137	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—psoriasis	0.000102	0.00137	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NDUFA5—psoriasis	0.000101	0.00135	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—psoriasis	9.88e-05	0.00133	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—TYK2—psoriasis	9.76e-05	0.00131	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—TYK2—psoriasis	9.76e-05	0.00131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.37e-05	0.00126	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—psoriasis	9.36e-05	0.00126	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—psoriasis	9.36e-05	0.00126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—psoriasis	9.24e-05	0.00124	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—psoriasis	9.09e-05	0.00122	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2S1—psoriasis	8.55e-05	0.00115	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—psoriasis	8.5e-05	0.00114	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—psoriasis	8.5e-05	0.00114	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—psoriasis	8.21e-05	0.0011	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—psoriasis	8.21e-05	0.0011	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—psoriasis	7.88e-05	0.00106	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKBIA—psoriasis	7.65e-05	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—psoriasis	7.56e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—psoriasis	7.56e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—psoriasis	7.56e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—psoriasis	7.56e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKBIA—psoriasis	7.04e-05	0.000945	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKBIA—psoriasis	7.04e-05	0.000945	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TYK2—psoriasis	6.27e-05	0.000841	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TYK2—psoriasis	5.77e-05	0.000774	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TYK2—psoriasis	5.77e-05	0.000774	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—psoriasis	5.5e-05	0.000739	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—psoriasis	5.46e-05	0.000732	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—psoriasis	5.19e-05	0.000696	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—psoriasis	5.07e-05	0.000681	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—psoriasis	5.02e-05	0.000674	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—psoriasis	5.02e-05	0.000674	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKB1—psoriasis	4.88e-05	0.000655	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—psoriasis	4.78e-05	0.000641	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—psoriasis	4.78e-05	0.000641	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—psoriasis	4.67e-05	0.000627	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—psoriasis	4.67e-05	0.000627	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKB1—psoriasis	4.49e-05	0.000603	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKB1—psoriasis	4.49e-05	0.000603	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.48e-05	0.000601	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—psoriasis	4.43e-05	0.000595	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—psoriasis	4.39e-05	0.000589	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CARM1—psoriasis	4.18e-05	0.00056	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—psoriasis	4.08e-05	0.000547	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—psoriasis	4.08e-05	0.000547	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—psoriasis	4.04e-05	0.000542	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—psoriasis	4.04e-05	0.000542	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.9e-05	0.000524	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—psoriasis	3.35e-05	0.000449	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—psoriasis	3.08e-05	0.000414	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—psoriasis	3.08e-05	0.000414	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—psoriasis	3.07e-05	0.000411	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—psoriasis	2.82e-05	0.000379	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—psoriasis	2.82e-05	0.000379	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAT—psoriasis	2.57e-05	0.000345	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—psoriasis	2e-05	0.000268	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—psoriasis	1.74e-05	0.000233	CbGpPWpGaD
